MindWalk Holdings (HYFT) Long-Term Deferred Tax (2021 - 2026)

MindWalk Holdings (HYFT) posted quarterly Long-Term Deferred Tax of $698866.8 for Q2 2026, up 4083.78% quarter-over-quarter from $16704.2 in Q4 2021.

MindWalk Holdings (HYFT) Long-Term Deferred Tax (2021 - 2026) Analysis & Trends

MindWalk Holdings (HYFT) has reported Long-Term Deferred Tax for 2 consecutive years, with $698866.8 the latest figure, recorded in Q2 2026.

In Q2 2026, Long-Term Deferred Tax changed N/A year-over-year to $698866.8; the TTM figure through Apr 2026 stood at $698866.8 (changed N/A YoY), while the FY2026 annual figure was $698866.8, changed N/A from the prior year.
Long-Term Deferred Tax rose to $698866.8 in Q2 2026 per HYFT's latest filing, from $16704.2 in the prior quarter.
Across five years, Long-Term Deferred Tax topped out at $698866.8 in Q2 2026 and bottomed at $698866.8 in Q2 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Roivant Sciences	26.16 Bn	26.85 Bn	1.16 Mn

Download Data

Date	Value
Apr 30, 2026	698,866.77
Oct 31, 2021	16,704.19